Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is ...
Ocular Therapeutix shares are trading higher Thursday after reports suggested Sanofi is preparing a revised bid for the ...
InvestorsHub on MSN
Sanofi weighs improved bid for Ocular Therapeutix following board rejection
Sanofi (EU:SAN) is reportedly preparing to submit a higher takeover proposal for Ocular Therapeutix (NASDAQ:OCUL) after the ...
Ocular Therapeutix (OCUL) added ~21% in the premarket on Thursday after the French publication La Lettre reported that Sanofi (SNY) is readying an improved takeover offer to acquire the U.S. eye ...
Taking control of Ocular would also give Sanofi access to its drug delivery platform Elutyx, which could have applications ...
Ocular Therapeutix (OCUL) has drawn investor attention after recent trading left the share price at US$11.28. Returns have ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...
Signs and symptoms of ocular surface disease could be significantly reduced within 4 days after treatment with shelf-stable ...
Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...
Ocular motor apraxia (OMA) is a neurological condition resulting in an inability to turn the eyes voluntarily in a horizontal manner. Ocular Motor Apraxia is known by a variety of terms. OMA is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback